Literature DB >> 1742846

The relative nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of cisplatin in the rat.

M M Jones1, M A Basinger, J A Beaty, M A Holscher.   

Abstract

An examination of the comparative nephrotoxicity in the rat of cisplatin, its hydrolysis product (mostly cis-[Pt(NH3)2Cl(H2O)]+ under the conditions applied), and cis-[Pt(NH3)2(guanosine)2]2+ revealed that these compounds differed significantly in the extent of renal damage they produced following their i.v. injection in Sprague-Dawley rats. The hydrolysis product was found to be the most toxic of the three complexes studied and produced nephrotoxicity at doses lower than those at which cisplatin was nephrotoxic. Under the conditions used, the i.v. administration of cis-[Pt(NH3)2(guanosine)2]2+ resulted in no observable signs of nephrotoxicity at levels at which an equimolar dose of cisplatin produces clear evidence of renal function impairment and morphological alterations. The nephrotoxicity of these complexes appears to be generally related to the ease with which they undergo nucleophilic substitution reactions. The lack of substantial nephrotoxicity found for cis-[Pt(NH3)2(guanosine)2]2+ suggests that the products resulting from the action of the DNA repair processes on platinated DNA do not contribute significantly to the nephrotoxicity of cisplatin. Renal platinum levels found following the administration of these compounds correlated with the degree of nephrotoxicity produced by each compound, but no general correlation of nephrotoxicity and renal platinum levels was found. The nephrotoxicity of cis-[Pt(NH3)2Cl(H2O)+ on a molar basis was estimated to be approximately 3 times as great as that of cisplatin itself.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1742846     DOI: 10.1007/bf00686332

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Acute and long-term nephrotoxicity of cis-platinum in man.

Authors:  S Groth; H Nielsen; J B Sørensen; A B Christensen; A G Pedersen; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration.

Authors:  C L Litterst
Journal:  Toxicol Appl Pharmacol       Date:  1981-10       Impact factor: 4.219

3.  A study of the protective effect of chloride salts on cisplatin nephrotoxicity.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

4.  Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations.

Authors:  D C Dobyan; J Levi; C Jacobs; J Kosek; M W Weiner
Journal:  J Pharmacol Exp Ther       Date:  1980-06       Impact factor: 4.030

5.  Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1984-10-01       Impact factor: 5.858

6.  The effect of cisplatin on renal ATPase activity in vivo and in vitro.

Authors:  J Uozumi; C L Litterst
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Correlation of structural and functional alterations.

Authors:  T W Jones; S Chopra; J S Kaufman; W Flamenbaum; B F Trump
Journal:  Lab Invest       Date:  1985-04       Impact factor: 5.662

8.  Cumulative renal tubular damage associated with cisplatin nephrotoxicity.

Authors:  M P Goren; R K Wright; M E Horowitz
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  An in vitro study comparing the cytotoxicity of three platinum complexes with regard to the effect of thiol depletion.

Authors:  E Smith; A P Brock
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

10.  The prevention of cisplatin-induced renal dysfunction by hydroxyl-containing dithiocarbamates.

Authors:  L V Reznik; E M Myazina; E I Shakchmatova; S P Gambaryan; V K Brovtsyn; Y V Natochin; M M Jones
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

View more
  8 in total

1.  Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.

Authors:  Ti Zhang; Shuang Cai; Chad Groer; Wai Chee Forrest; Qiuhong Yang; Eva Mohr; Justin Douglas; Daniel Aires; Sandra M Axiak-Bechtel; Kimberly A Selting; Jeffrey A Swarz; Deborah J Tate; Jeffrey N Bryan; M Laird Forrest
Journal:  J Pharm Sci       Date:  2016-05-04       Impact factor: 3.534

2.  Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.

Authors:  P H Cashin; H Ehrsson; I Wallin; P Nygren; H Mahteme
Journal:  Eur J Clin Pharmacol       Date:  2012-09-16       Impact factor: 2.953

Review 3.  Cisplatin ototoxicity and protection: clinical and experimental studies.

Authors:  Leonard P Rybak; Debashree Mukherjea; Sarvesh Jajoo; Vickram Ramkumar
Journal:  Tohoku J Exp Med       Date:  2009-11       Impact factor: 1.848

4.  Short-Term Diet Restriction but Not Alternate Day Fasting Prevents Cisplatin-Induced Nephrotoxicity in Mice.

Authors:  Evrin Gunebakan; Esra Yalcin; Esra Cikler Dulger; Ahmet Yigitbasi; Nilay Ates; Aysun Caglayan; Mustafa C Beker; Kazim Sahin; Hasan Korkaya; Ertugrul Kilic
Journal:  Biomedicines       Date:  2020-02-03

5.  Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.

Authors:  F E de Jongh; R N van Veen; S J Veltman; R de Wit; M E L van der Burg; M J van den Bent; A S Th Planting; W J Graveland; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

6.  Pressure tuning infrared spectroscopic study of cisplatin-induced structural changes in a phosphatidylserine model membrane.

Authors:  K D Taylor; R Goel; F H Shirazi; M Molepo; P Popovic; D J Stewart; P T Wong
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

7.  Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometric (LC/ESI-MS/MS) Study for the Identification and Characterization of In Vivo Metabolites of Cisplatin in Rat Kidney Cancer Tissues: Online Hydrogen/Deuterium (H/D) Exchange Study.

Authors:  Raju Bandu; Hyun Soo Ahn; Joon Won Lee; Yong Woo Kim; Seon Hee Choi; Hak Jin Kim; Kwang Pyo Kim
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

Review 8.  Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies.

Authors:  Angela Callejo; Lara Sedó-Cabezón; Ivan Domènech Juan; Jordi Llorens
Journal:  Toxics       Date:  2015-07-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.